The Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) is a collaborative research network with the goal of discovering targeted agents to prevent or intercept the development of cancer in higher-risk populations.
On This Page
About the Cancer Prevention-Interception Targeted Agent Discovery Program
The approach to cancer prevention and interception in higher-risk cohorts is to use preventive measures specifically tailored for individual risk factors, an approach referred to as precision cancer prevention-interception. Success of precision cancer prevention-interception depends on two complementary steps:
- First, higher-risk individuals need to be identified, e.g., through screening and early detection of precursors/precancers, some of which may progress to cancer, and testing for genetic susceptibility.
- Second, innovative, safe, and efficacious measures designed to reduce cancer risk or molecularly/immunologically intercept, arrest, and possibly eliminate precancer in these higher-risk individuals are needed to complement or replace surgical resection or ablation.
While current cancer interception strategies predominantly rely on surgical interventions, CAP-IT was created to discover and bring risk-tailored targeted agents to the higher-risk populations for cancer prevention and interception.
The ultimate goals of CAP-IT are to advance newly discovered efficacious cancer preventive or interceptive agents to the existing NCI preclinical and clinical development pipelines: PREVENT Program for further development and Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) for early phase clinical trials.
View the CAP-IT Network website public webpage.
CAP-IT Teams
- CAP-IT at Fox Chase Cancer Center
-
Principal Investigator (PI)/Admin Core: Margie Clapper, Ph.D.
PI Website: Clapper Lab
Center RePORT: U54 CA272686-01Institution: The Research Institute of Fox Chase Cancer Center
Investigator(s) Role Lab Page Margie Clapper, Ph.D. Project 1 Lead Clapper Lab Edna Cukierman, Ph.D. Project 2 Lead Cukierman Lab Wen-Chi Chang, Ph.D. Projects 1&2 Co-investigator Chang lab Eric Ross, Ph.D., ScM Informatics Core Lead Ross Lab Joseph Treat, M.D. Co-investigator Treat Lab Erica Golemis, Ph.D. Co-investigator Golemis Lab Michael Hall, M.D., M.S. Co-investigator Hall Lab Roland L. Dunbrack, Jr, Ph.D. Administrative core Co-investigator Dunbrack Lab - CAP-IT Center for LNP RNA Immunoprevention
-
Principal Investigator, Project 1 Lead, and Administrative Core Lead: Steven Lipkin, M.D. Ph.D.
PI Website: Lipkin Lab
Center RePORT: U54 CA272688-01Institution: Weill Medical College of Cornell University
Investigator(s) Role Lab Page Naseer Altorki, M.D. Project 2 Lead Altorki Lab Timothy McGraw, Ph.D. Project 2 Co-lead McGraw Lab Vivek Mittal, Ph.D. Project 2 Co-lead Mittal Lab Julie Boyer, Ph.D. Co-core Lead Boyer Lab Bhavneet Bhinder, M.S. Administrative core Co-investigator Bhinder Lab Olivier Elemento, Ph.D. Admin core lead/Computational Biology Elemento Lab Institution: German Cancer Research Center (DKFZ) Heidelberg, Germany
Investigator(s) Role Lab Page Mathias Kloor, M.D. Ph.D. Project 1 Co-investigator Kloor Lab Aysel Ahadova, Ph.D. Project 1 Co-investigator Ahadova Lab Institution: Sloan Kettering Institute
Investigator(s) Role Lab Page Zsofia Stadler, M.D. Project 1 Co-investigator Stadler Lab Institution: Cornell Engineering
Investigator(s) Role Lab Page Shaoyi Jiang, Ph.D. Projects 1&2 Co-investigator Jiang Lab Institution: Dana-Farber Cancer Institute
Investigator(s) Role Lab Page Derin Keskin, Ph.D. Core Lead Keskin Lab Institution: Broad Institute
Investigator(s) Role Lab Page Gad Getz, Ph.D. Core Co-lead Getz Lab - CAP-IT Center Against MGUS Progression
-
Principal Investigator: Yong Li, Ph.D.
PI Website: Li Lab
Center RePORT: U54 CA272691-01A1Institution: Baylor College of Medicine
Investigator(s) Role Lab Page Xinfang Yu, Ph.D. Project 2 Lead Yu Lab Institution: University of Arkansas for Medical Sciences
Investigator(s) Role Lab Page Fenghuang Zhan, M.D. Ph.D. Project 1 Lead Zhan Lab Eric Siegel, M.S. Project 1 Co-investigator Siegal Lab John Shaughnessy, Ph.D. Computational Tumor Immunology Core Lead Shaughnessy Lab Timothy Ashby, Ph.D. Co-core Leader Ashby Lab Institution: Duke University
Investigator(s) Role Lab Page Ken Young, M.D. Ph.D. Project 2 Co-investigator Young Lab Zijun Xu-Monette, Ph.D. Project 2 Co-investigator Xu-Monette Lab - Data and Resource Coordination Center for Cancer Prevention-Interception Targeted Agent Discovery Program
-
Principal Investigator: Alan Hutson, Ph.D.
PI Website: Hutson Lab
Co-Principal Investigator/MPI: Song Liu, Ph.D.
Co-PI Website: Song Liu Lab
Center RePORT: 3U24CA274159-02S1Institution: Roswell Park Comprehensive Cancer Center
Investigator(s) Role Lab Page Qianqian Zhu, Ph.D. Co-investigator Zhu Lab Martin Morgan, Ph.D. Co-investigator Morgan Lab Lei Wei, Ph.D. Co-investigator Wei Lab Tao Liu, Ph.D. Co-investigator Tao Liu Lab Jianmin Wang, Ph.D. Co-investigator Wang Lab Mark Long, Ph.D. Co-investigator Long Lab Spencer Rosario, Ph.D. Co-investigator Rosario Lab Henry Withers, Ph.D. Co-investigator Pending Institution: University of Nebraska-Lincoln
Investigator(s) Role Lab Page Chi Zhang, Ph.D. Co-investigator Pending
Contact the Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
Program Contact(s)
Contact CAP-IT
Email: CAP-IT@nih.gov